Bladder cancer develops 6 years earlier in current smokers: Analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association

2008 ◽  
Vol 16 (1) ◽  
pp. 64-69 ◽  
Author(s):  
Shiro Hinotsu ◽  
Hideyuki Akaza ◽  
Tsuneharu Miki ◽  
Hiroyuki Fujimoto ◽  
Nobuo Shinohara ◽  
...  
2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 142s-142s ◽  
Author(s):  
D.T. Sinulingga ◽  
A. Kadir ◽  
D. Purwanto ◽  
K. Kardinah ◽  
E. Suzanna ◽  
...  

Background and context: Breast cancer screening programs by mobile mammography have been done since 2005 for Jakarta and around by collaboration of Dharmais National Cancer Center with The Indonesia Breast Cancer Foundation and Jakarta Health Department. Every activity, mobile mammography has been examined 50 persons for 60-80 times yearly. For 2015 there were 3493 examinations with 529 cases (15.1%) were abnormal which 43 from that cases (8.1%) are suspect malignancy. All that data were compile with early detection and cancer registry data to know the real cancer, but there were no malignancy and only 15 benign cases had come to follow-up to Dharmais NCC. The result is no malignancy. To compile the mobile mammography data with detection unit and cancer registry data were difficult because of the difference terms of the variables. National Cancer Registry of Indonesia has been announced by Ministry of Health since 2016. The coverage of cancer that diagnosed in 2008-2012 in Jakarta just 30.7%. One of the sources of data are screening data. In Indonesia, screening programs for breast and cervix cancer have been done sporadically, including at Jakarta. Unfortunately for 2008-2012 diagnose year, there were no data can compile to cancer registry because there were no address data and name. So we collaborate to improve the data variables for cancer registration system. Aim: To conduct the mobile mammography screening data as one of the sources data for cancer registration to improve the coverage in Jakarta and to prepare the breast specific cancer registry system. Strategy/Tactics: Cancer Registry, Early Detection, Radiology and Pathology Unit was collaborating with The Indonesia Breast Cancer Foundation to improve the variables. Program/Policy process: We to improve the variables and their operational definition especially for name, address and birth date include risk factors and physical examinations variables. The palpations of breast was conduct by midwives or doctors before the examination with mammography. Cancer registration variables definition is the standard, so the name variable is the name that written in the National Identity Card, include the birth date and address. Information system department in Dharmais NCC has made the program to this data system and have been take place since July 2017. Outcomes: There were 1462 data that have been in hospital data based for mobile mammography with 237 cases (16.2%) were abnormal which 14 cases (5.9%) are suspect malignancy. Only 5 suspect malignancy cases had more examination in Dharmais NCC and all of them were diagnosed breast malignancy. What was learned: Standardization of variable definitions is very important for cancer registry data source to improve the coverage especially for early stage finding cases. But to know the standard diagnose and to follow the cases real conditions, we have to make a good and clear referral system networking.


2019 ◽  
Vol 18 (5) ◽  
pp. 5-11
Author(s):  
G. V. Petrova ◽  
O. P. Gretsova ◽  
V. V. Starinsky

The purpose of the study was to compare data on the cancer incidence rates for 2016 between the official reports on cancer statistics and federal cancer registry, collected in December 2018.Material and Methods. The study estimated the total data on 18 parameters from 35 regions of Russia, covering 66.3 million people (2016). The database of the Russian cancer registry and the database containing reports on the state cancer statistics were used. The cancer statistics/cancer registry ratio was assessed.Results. No differences in cancer incidence between the official reports on cancer statistics and cancer registry data were found. In the official reports on cancer statistics, the mortality rate, the proportion of posthumously recorded patients per 100 newly diagnosed, the proportion of deaths from diseases not related to cancer per 100 deceased patients, the cancer prevalence and the prevalence rate of unspecified malignant tumors were slightly reduced (to 10 %, 9 %, 5 %, and 4 %, respectively), and the rate of cancer detection, the proportion of histologically verified diagnoses and the proportion of cancers detected in stage III were increased (to 19 %, 10 % and 14 %, respectively) compared to those in cancer registry data.Conclusion. Improvement in the quality and completeness of information about cancer patients is associated rather with increasing the annual report length than with the need to improve the cancer registration system itself.


Author(s):  
Sophia Amjad ◽  
Rachael Williams ◽  
Rachael Brannan ◽  
Tariq Malik ◽  
Janet Valentine

ABSTRACTObjectivesTo enhance the research value and capability of its primary care database, the Clinical Practice Research Datalink (CPRD) has collaborated with Public Health England (PHE)’s National Cancer Registration and Analysis Service to facilitate access to linked cancer registration data for use in research, pharmacovigilance, drug monitoring and health outcomes analysis. Since 2009, access to this linked resource has been co-managed by CPRD and PHE, through two parallel, independent approvals processes: (a) the MHRA Independent Scientific Advisory Committee (ISAC) and (b) the PHE Office for Data Release (ODR). In upholding the Office for Life Science Ministerial Industry Strategy Group (Health Data Programme)’s vision to minimise process barriers to accessing real world data, CPRD and PHE have worked together to unify and streamline these two processes into a single end-to-end application and approval process. ApproachEach organisation reviewed each other’s approval processes to achieve an improved mutual understanding of the respective organisation’s governance approach, the risk based assessments applied to disclosure risk, risk appetites and policies, with the goal to harmonise these into a single approval process. ResultsCPRD and PHE are finalising a contract establishing a clear operating framework allowing CPRD to grant approval to researchers for the use of linked cancer registry data. The contract names CPRD as a joint data controller and sets out the purposes for processing, the manner of processing and the means by which joint data controller responsibilities will be satisfied. An associated service level agreement is in discussion which will enable robust timelines and performance management for both organisations. These developments are important milestones towards achieving the single approval process by allowing CPRD to review applications for cancer registry data in-house, simultaneously to the ISAC review. ConclusionThe strong relationship built between CPRD and PHE, and willingness to develop a single application and approval process, will strengthen and streamline access to these data, whilst assuring patients and the public that scientific integrity is maintained and proportionate information governance checks are in place. Upon completion of this work, applicants will experience associated faster review and feedback time, ultimately leading to faster approvals. Researchers wishing to utilise these linked data will soon be able to submit one application to ISAC, have one point of contact and one approval.


2014 ◽  
Vol 13 (5) ◽  
pp. 156-157
Author(s):  
S. Mamoudou Garba ◽  
H. Hami ◽  
H. Mahamadou Zaki ◽  
A. Soulaymani ◽  
H. Nouhou ◽  
...  

2019 ◽  
Vol 82 (S 01) ◽  
pp. S62-S71 ◽  
Author(s):  
Volker Arndt ◽  
Bernd Holleczek ◽  
Hiltraud Kajüter ◽  
Sabine Luttmann ◽  
Alice Nennecke ◽  
...  

AbstractPopulation-based cancer registries have a long-standing role in cancer monitoring. Scientific use of cancer registry data is one important purpose of cancer registration, but use of cancer registry data is not restricted to cancer registries. Cancer registration in Germany is currently heading towards population-based collection of detailed clinical data. This development together with additional options for record linkage and long-term follow-up will offer new opportunities for health services and outcome research. Both regional population-based registries and the German Centre for Cancer Registry Data (ZfKD) at the Robert Koch-Institute as well as international cancer registries and consortia or organizations may provide external researchers access to individual or aggregate level data for secondary data analysis. In this review, we elaborate on the access to cancer registry data for research purposes, availability of specific data items, and options for data linkage with external data sources. We also discuss as well as on limitations in data availability and quality, and describe typical biases in design and analysis.


2012 ◽  
Vol 53 (5) ◽  
pp. 304 ◽  
Author(s):  
Weranja K. B. Ranasinghe ◽  
Daswin De Silva ◽  
M.V.C. De Silva ◽  
Tamra I J Ranasinghe ◽  
Nathan Lawrentschuk ◽  
...  

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Maximilian Richter ◽  
Lena Sonnow ◽  
Amir Mehdizadeh-Shrifi ◽  
Axel Richter ◽  
Rainer Koch ◽  
...  

Abstract Objectives To evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison. Methods Between 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR). Results Relative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001). Conclusions Our findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.


2020 ◽  
Vol 128 (10) ◽  
pp. 107004
Author(s):  
Nathan C. Coleman ◽  
Richard T. Burnett ◽  
Majid Ezzati ◽  
Julian D. Marshall ◽  
Allen L. Robinson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document